Dr. Farzad Mostashari Discusses Whether Payment Incentives for Achieving Meaningful Use is Enough

Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.

Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.

Elinzanetant significantly reduced the frequency and severity of vasomotor symptoms, known as hot flashes, compared with placebo across body mass index (BMI) and smoking status subgroups.

A group of experts discusses the use of continuous glucose monitoring (CGM) technology in diabetes and its transformative potential in managing the disease.

Recurrence-free survival rates were similar, even when patients quit adjuvant immunotherapy early, according to a new report.

These advances are designed to improve uptake of biomarker-driven cancer care and reduce treatment delays.